0%
Print report
Variant interpretation report

TP53 c.63C>T, p.Asp21=

NM_000546.5:c.63C>T NP_000537.3:p.(Asp21=) Synonymous · exon 2 View identifiers
Classification
Benign

Variant description:

The TP53 NM_000546.5:c.63C>T (NP_000537.3:p.(Asp21=)) synonymous variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be Benign.

Five-step scale from benign to pathogenic. This variant is benign. Select a step to read what it means.

Benign.A benign classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About TP53

TP53 encodes the p53 tumor suppressor protein, a transcription factor that responds to cellular stress such as DNA damage by switching on genes that trigger cell cycle arrest, DNA repair, senescence, or programmed cell death. In healthy cells, p53 is kept at low levels by constant degradation, but stress signals stabilize and activate it to protect against damaged cells surviving and dividing. Inherited mutations in TP53 cause Li-Fraumeni syndrome, a condition marked by a high risk of developing multiple cancers at a young age. TP53 is the most commonly mutated gene across human cancers, and loss of its normal function promotes tumor growth, spread, drug resistance, and genomic instability.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen TP53 VCEP v2.4. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 3
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 3
BA1Stand alone
BA1 · stand alone

Met: gnomAD v4.1 South Asian FAF 0.0037098 exceeds the TP53 VCEP BA1 threshold of 0.001 in a 91,088-allele subgroup.

BP4Supporting
BP4 · supporting

Met at supporting: maximum SpliceAI delta 0.004 is below the TP53 VCEP BP4 silent-variant threshold of 0.1.

BP7Supporting
BP7 · supporting

Met at supporting: synonymous c.63C>T is outside the core splice motif and has maximum SpliceAI delta 0.004, below the 0.1 threshold.

Recorded classification: Benign

Benign: BA1 stand-alone benign plus BP4 and BP7 supporting criteria produce a total of -10 points under the TP53 Expert Panel framework.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
387 / 1,614,004 alleles

gnomAD v4.1: 387 / 1,614,004 alleles. Recorded AF 0.000239776. Recorded homozygote count 4.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.000535148; MAF= 0.05351%, 134/250398 alleles, homozygotes = 2) and has highest observed frequency in the South Asian population (AF= 0.00439114; MAF= 0.43911%, 134/30516 alleles, homozygotes = 2); grpmax FAF= 0.00378627.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0004893964110929853, 9/18390 alleles, homozygotes = 0).

SpliceAI score
0.004 maximum delta

Recorded SpliceAI maximum delta score: 0.004. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
11 reported laboratory submissions

6 Benign · 5 Likely benign. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen TP53 VCEP v2.4, with the data and sources behind each one.

28 criteria with recorded statuses: 3 met · 3 not met · 6 not assessed · 16 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

For the three requested consequence/LOF criteria, the variant is a synonymous exon 2 SNV, not a null variant or a protein-length-changing indel; PM4 and BP3 are also explicitly not applicable in the TP53 VCEP CSPEC.

Exact-variant literature reviewed for consequence context includes PMID:32000721, PMID:20436704, and PMID:18798306; none provides variant-specific evidence that changes the VCEP applicability of PVS1, PM4, or BP3.

All five requested criteria are not applicable under the TP53 VCEP v2.4 rules: PS1, PM1, and PM5 require protein-altering or missense routes that do not include this synonymous variant, while PP2 and BP1 are explicitly not applicable in the VCEP specification.

The TP53 VCEP governs all five requested criteria.

PS4 and PP4 could not be assigned because the available observations do not establish the VCEP's required LFS point categories or PP4 VAF/panel conditions.

PP5, BP5, and BP6 are explicitly not applicable under the TP53 VCEP.

For this synonymous exon 2 variant, the TP53 VCEP computational paths yield BP4 Supporting and BP7 Supporting from the same no-splice-impact SpliceAI result; PP3 is not met because the VCEP PP3 threshold is not reached.

The same SpliceAI prediction is not double-counted as separate independent predictions; BP7 is applied only as the VCEP's additional code after BP4 is met.

Met · 3

BA1 Stand aloneVCEPMet: gnomAD v4.1 South Asian FAF 0.0037098 exceeds the TP53 VCEP BA1 threshold of 0.001 in a 91,088-allele subgroup. Details ▾Hide ▴
Reasoning

BA1 is met at stand-alone strength. Using the most recent all-comers gnomAD v4.1 data, the South Asian continental ancestry group has a filtering allele frequency (FAF) of 0.0037098, with 369 alternate alleles among 91,088 tested alleles and 4 homozygotes. This exceeds the VCEP threshold of FAF ≥0.001, and the group exceeds the minimum 2,000 alleles tested and minimum 2 alleles present. South Asian is not one of the founder-effect groups excluded by the rule. The total gnomAD v4.1 AF is 0.000239776 (387/1,614,004 alleles), but BA1 is determined from the qualifying continental subgroup FAF. The VCEP permits use of the most recent gnomAD version when available; the non-cancer subset is not needed because the governing rule does not require it.

VCEP rule
Filtering allele frequency (FAF) of ≥ 0.001 or 0.1% in gnomAD continental subpopulations of a single genetic ancestry group (excluding genetic ancestry groups influenced by founder effects, such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”). Genetic ancestry group must have ≥2,000 alleles tested and a minimum of 2 alleles present.
Evidence considered
  • gnomAD v4.1 all-comers: total AF 0.000239776 (387/1,614,004 alleles), homozygotes 4; South Asian AF 0.00405103 (369/91,088 alleles), homozygotes 4; South Asian grpmax FAF 0.0037098.
  • The South Asian group has 91,088 alleles tested and 369 variant alleles, satisfying the VCEP minimum of ≥2,000 alleles tested and at least 2 alleles present.
  • The TP53 VCEP excludes Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and Remaining groups for this rule; South Asian is not excluded.
Sources
BP4 SupportingVCEPMet at supporting: maximum SpliceAI delta 0.004 is below the TP53 VCEP BP4 silent-variant threshold of 0.1. Details ▾Hide ▴
Reasoning

The variant is a synonymous exon 2 substitution, not a canonical ±1,2 splice-site variant. The TP53 VCEP BP4 supporting rule for silent variants outside ±1,2 positions requires SpliceAI ≤ 0.1. c.63 is not within the canonical splice-site positions, and the observed SpliceAI component scores are DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, and DS_DL 0.001, with maximum delta 0.004. Therefore BP4 Supporting is met. No exact c.63C>T/p.Asp21=/p.D21= row was found in the governing PP3-BP4 lookup spreadsheet; the separate single-amino-acid-deletions spreadsheet contains only the different p.Asp21del/c.61_63delGAC deletion at this position.

VCEP rule
**Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1
Evidence considered
  • NM_000546.5:c.63C>T is synonymous in exon 2 and is outside the canonical ±1,2 splice-site positions.
  • SpliceAI result: DS_AG=0.001, DS_AL=0.004, DS_DG=0.003, DS_DL=0.001; maximum delta=0.004.
  • The TP53 VCEP flowchart assigns BP4 to silent variants with SpliceAI <= 0.1, and the VCEP rule specifies this path for silent variants outside ±1,2 positions.
  • PP3-BP4-codes.xlsx was searched for c.63C>T, p.Asp21=, and p.D21=; no exact matching row was found.
  • TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx was searched; its p.Asp21del/c.61_63delGAC row is not the assessed synonymous variant.
Still missing
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in PP3-BP4-codes.xlsx.
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx; the located p.Asp21del/c.61_63delGAC row is a different variant.
Sources
BP7 SupportingVCEPMet at supporting: synonymous c.63C>T is outside the core splice motif and has maximum SpliceAI delta 0.004, below the 0.1 threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous and lies outside the TP53 VCEP core splice motif, defined as the last three nucleotides and first nucleotide of the exon. The governing BP7 supporting rule requires a synonymous variant outside that motif and SpliceAI ≤ 0.1, with BP4 met. c.63 is outside the exon-boundary core motif, BP4 Supporting is met, and the maximum SpliceAI delta is 0.004 (DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, DS_DL 0.001). BP7 Supporting is therefore met without using nucleotide conservation. No exact variant row was found in PP3-BP4-codes.xlsx or in the single-amino-acid-deletions spreadsheet; the latter contains a distinct p.Asp21del entry.

VCEP rule
A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023 (PMID: 37352859).
Evidence considered
  • NM_000546.5:c.63C>T is a synonymous exon 2 variant; the assessed coding position is outside the VCEP core splice motif of the last three nucleotides and first nucleotide of the exon.
  • SpliceAI result: DS_AG=0.001, DS_AL=0.004, DS_DG=0.003, DS_DL=0.001; maximum delta=0.004.
  • The TP53 VCEP flowchart states that BP7 is added to BP4 for a silent variant outside the core splice motif when SpliceAI <= 0.1.
  • The reviewed exact-variant paper extracts did not identify a variant-specific RNA splicing assay for c.63C>T; no RNA assay is needed for the VCEP BP7 Supporting path.
  • PP3-BP4-codes.xlsx and TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx were searched for c.63C>T, p.Asp21=, and p.D21=; neither contained an exact row.
Still missing
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in PP3-BP4-codes.xlsx.
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx; the located p.Asp21del/c.61_63delGAC row is a different variant.
  • No variant-specific RNA splicing assay result was identified in the reviewed case evidence; BP7 Supporting is evaluated from the VCEP SpliceAI path, not the stronger RNA-assay path.
Sources

Not met · 3 · evaluated, threshold not reached

PM2 VCEPNot met: gnomAD v4.1 total AF 0.000239776 exceeds the TP53 PM2 cutoff of 0.00003, with South Asian AF 0.00405103 also exceeding 0.00004. Details ▾Hide ▴
Reasoning

PM2 is not met at supporting strength. The governing TP53 VCEP rule requires total allele frequency <0.00003 in gnomAD, with any ancestry group containing multiple alleles required to have frequency <0.00004. The default all-comers gnomAD v4.1 total AF is 0.000239776 (387/1,614,004 alleles), exceeding 0.00003; its South Asian subgroup also has 369 alleles at AF 0.00405103, exceeding 0.00004. The gnomAD v2.1 all-comers total AF is likewise 0.000535148 (134/250,398 alleles), and the non-cancer subsets do not rescue the criterion: gnomAD v2.1 non-cancer exomes AF 0.000561978 and gnomAD v3.1 non-cancer genomes AF 0.000135248. The VCEP's CHIP recalculation pathway is conditional on no population rule codes being met, and BA1 is met here, so that pathway does not apply.

VCEP rule
This rule should be applied at supporting level. Variant should have an allele frequency of less than 0.00003 (0.003%) in gnomAD or another large sequenced population. If multiple alleles are present within any genetic ancestry group, allele frequency in that group must be <0.00004 (0.004%). Genetic ancestry groups influenced by founder effects (such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”) should be ignored.
Evidence considered
  • gnomAD v4.1 all-comers: total AF 0.000239776 (387/1,614,004 alleles), homozygotes 4; South Asian AF 0.00405103 (369/91,088 alleles), homozygotes 4.
  • gnomAD v2.1 all-comers: total AF 0.000535148 (134/250,398 alleles), homozygotes 2; South Asian AF 0.00439114 (134/30,516 alleles), homozygotes 2.
  • gnomAD v2.1 non-cancer exomes: AF 0.000561978 (133/236,664 alleles), homozygotes 2.
  • gnomAD v3.1 non-cancer genomes: AF 0.000135248 (20/147,876 alleles), homozygotes 0; this is still above the PM2 total-frequency cutoff.
Sources
PP3 VCEPNot met: maximum SpliceAI delta 0.004 is below the TP53 VCEP PP3 threshold of 0.2 for exonic silent splice variants. Details ▾Hide ▴
Reasoning

The variant is synonymous in exon 2 (NM_000546.5:c.63C>T; NP_000537.3:p.(Asp21=), p.(D21=)). The TP53 VCEP PP3 supporting rule covers exonic silent variants when SpliceAI is ≥ 0.2. The available SpliceAI result has DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, and DS_DL 0.001, with a maximum delta of 0.004, so the PP3 splice-impact threshold is not met. The governing PP3-BP4 lookup spreadsheet was searched for c.63C>T, p.Asp21=, and p.D21= without an exact entry; the single-amino-acid-deletions spreadsheet was also searched and contains p.Asp21del/c.61_63delGAC, which is a different in-frame deletion rather than this synonymous variant.

VCEP rule
**Exonic (including silent variants and apparent “missense” variants or “single amino acid inframe deletions” for which there is a predicted splice effect) or Intronic Splice Variants (excluding ± 1,2 positions):** SpliceAI ≥ 0.2
Evidence considered
  • NM_000546.5:c.63C>T is a synonymous exon 2 variant, annotated NP_000537.3:p.(Asp21=) and NP_000537.3:p.(D21=).
  • SpliceAI result: DS_AG=0.001, DS_AL=0.004, DS_DG=0.003, DS_DL=0.001; maximum delta=0.004.
  • ClinGen TP53 VCEP Flowchart for application of PP3, BP4, and BP7: exonic splice variants, including silent variants with predicted splice effect, require SpliceAI >= 0.2 for PP3.
  • PP3-BP4-codes.xlsx was searched for c.63C>T, p.Asp21=, and p.D21=; no exact matching row was found.
  • TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx was searched; its p.Asp21del/c.61_63delGAC row is an in-frame deletion and not the assessed synonymous variant.
Still missing
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in PP3-BP4-codes.xlsx.
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx; the located p.Asp21del/c.61_63delGAC row is a different variant.
Sources
BS1 VCEPNot met: South Asian gnomAD v4.1 FAF 0.0037098 is above the BS1 upper limit of 0.001 and instead meets BA1. Details ▾Hide ▴
Reasoning

BS1 is not met. The qualifying South Asian gnomAD v4.1 continental subgroup has FAF 0.0037098, which is above the BS1 interval of ≥0.0003 but <0.001; therefore it does not fall within the VCEP BS1 range. The same population data meet the separate BA1 threshold of ≥0.001. The subgroup has 91,088 alleles tested and 369 alternate alleles, and South Asian is not an excluded founder-effect group.

VCEP rule
Filtering allele frequency (FAF) of ≥ 0.0003 but < 0.001 in gnomAD continental subpopulations of a single genetic ancestry group (excluding genetic ancestry groups influenced by founder effects, such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”). Genetic ancestry group must have ≥2,000 alleles tested and a minimum of 2 alleles present.
Evidence considered
  • gnomAD v4.1 all-comers: South Asian AF 0.00405103 (369/91,088 alleles), homozygotes 4, and grpmax FAF 0.0037098.
  • The observed South Asian FAF 0.0037098 is not within the VCEP BS1 interval of ≥0.0003 but <0.001.
Sources

Not assessed · 6 · no assessment recorded

PS2 VCEPNot assessed: no documented proband cancer phenotype or confirmed maternity, paternity, and de novo status is available for assigning PS2 points. Details ▾Hide ▴
Reasoning

The TP53 VCEP requires de novo points to be tallied from confirmed maternity and paternity and the proband's LFS-associated cancer type. The available evidence reports c.63C>T in cancer cohorts but provides no case-specific proband phenotype, parental testing, maternity, paternity, or confirmed de novo observation. Therefore PS2 cannot be assessed. The governing LFS cancer table was searched under c.63C>T, p.Asp21=, and p.D21=; no variant-specific pre-assigned PS2 code was found.

VCEP rule
_De novo_ points should be tallied using the table for tallying proband points based on whether maternity and paternity have been confirmed and the type of cancer(s) seen in the proband. ... 1 point
Evidence considered
  • No case-specific parental testing, maternity, paternity, or confirmed de novo result is present in the reviewed evidence.
  • PMID:32000721 reports c.63C>T in 2 breast-cancer patients and 1 healthy female control, but reports no de novo or parental testing.
  • PMID:20436704 reports rs1800369C>T [D21D] as a germ-line polymorphism in a Korean NSCLC cohort, with no de novo or parental testing.
  • The VCEP LFS cancer/points table was searched for c.63C>T, p.Asp21=, and p.D21=; no variant-specific PS2 assignment was found.
Still missing
  • No confirmed de novo observation with parental testing, maternity, and paternity is documented.
  • No case-specific proband LFS-associated cancer type is documented for point assignment.
  • No entry for c.63C>T, p.Asp21=, or p.D21= was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/TP53/fulltext/Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf.txt.
Sources
PS4 VCEPNot assessed: two breast-cancer cases versus one control gave OR 2.07 (95% CI 0.18-24.15), but no VCEP-defined LFS point-qualifying phenotype was reported. Details ▾Hide ▴
Reasoning

The TP53 VCEP PS4 rule assigns points for Revised Chompret criteria (0.5), Classic LFS criteria (1), or HER2-positive breast cancer diagnosed before age 40 (0.5), with Supporting at 1-1.5 points, Moderate at 2-3.5, Strong at 4-7.5, and Very Strong at >=8. The PS4-Points-Table.pdf full text was searched for c.63C>T, p.Asp21=, and p.D21=; no variant-specific row was present. PMID:32000721 reports c.63C>T in 2 of 30 breast-cancer patients and 1 of 30 healthy female controls. Treating this as a case-control comparison, the uncorrected odds ratio is (2 x 29)/(28 x 1) = 2.07 with a Woolf 95% CI of 0.18-24.15; this does not establish the VCEP's required LFS point category, and the paper does not report the patients' ages, HER2 status, Revised Chompret status, or Classic LFS status. PMID:20436704 reports rs1800369C>T [D21D] as a germline polymorphism with MAF 0.392 in a Korean NSCLC cohort, but supplies no VCEP PS4 point-qualifying phenotype. Therefore PS4 cannot be assigned from the available evidence.

VCEP rule
PS4 points: Revised Chompret 0.5, Classic LFS criteria 1, or HER2+ breast cancer below age 40 0.5; PS4_Supporting = 1-1.5 points, PS4_Moderate = 2-3.5 points, PS4 = 4-7.5 points, PS4_Very Strong = >=8 points.
Evidence considered
  • PS4-Points-Table.pdf, page 1: Revised Chompret = 0.5 point, Classic LFS criteria = 1 point, HER2-positive breast cancer under age 40 = 0.5 point; PS4_Supporting = 1-1.5 points, PS4_Moderate = 2-3.5 points, PS4 = 4-7.5 points, and PS4_Very Strong = >=8 points.
  • PMID:32000721, Results/Table 3: TP53 c.63C>T (p.Asp21Asp) appeared in 2 breast-cancer patients and 1 healthy female control. The computed case-control odds ratio was 2.07, with Woolf 95% CI 0.18-24.15.
  • PMID:20436704, Results paragraph 1: rs1800369C>T [D21D], corresponding to c.63C>T/p.(D21=), was reported as a germline polymorphism with MAF 0.392 in a cohort of 176 Korean NSCLC patients; no PS4 point-qualifying phenotype was given.
Still missing
  • PS4-Points-Table.pdf was searched for c.63C>T, p.Asp21=, and p.D21=; no entry for this variant was found.
  • The available case report lacks patient ages, HER2 status, Revised Chompret classification, and Classic LFS classification needed to assign PS4 points.
Sources
PP1 VCEPNot assessed: no affected relatives, obligate carriers, or countable cosegregating meioses are documented for applying PP1. Details ▾Hide ▴
Reasoning

The TP53 VCEP counts meioses only for individuals who carry the variant and have a relevant LFS-associated cancer, including through unaffected obligate carriers. No family pedigree, affected relative testing, obligate-carrier information, or countable cosegregating meioses is documented. The literature reports unrelated cohort observations of the variant, not familial segregation. Therefore PP1 cannot be assessed. The governing LFS cancer table was searched under c.63C>T, p.Asp21=, and p.D21=; no variant-specific pre-assigned PP1 code was found.

VCEP rule
Meioses should be counted for individuals who both carry the variant and have a relevant cancer (see LFS cancers table). Meioses can be counted through unaffected obligate carriers. ... Cosegregation must be observed in 3-4 meioses in/across 1 or more families
Evidence considered
  • No family segregation data, affected-relative testing, obligate-carrier status, or meiosis count is present in the reviewed case evidence.
  • PMID:32000721 reports c.63C>T in 2 breast-cancer patients and 1 healthy female control without familial segregation analysis.
  • PMID:20436704 reports rs1800369C>T [D21D] in a 176-patient Korean NSCLC cohort without familial segregation analysis.
  • PMID:18798306 reports rs1800369 D21D as monomorphic in more than 200 Irish individuals and provides no segregation data.
  • The VCEP LFS cancer/points table was searched for c.63C>T, p.Asp21=, and p.D21=; no variant-specific PP1 assignment was found.
Still missing
  • No family pedigree or tested affected relatives are documented.
  • No countable meioses involving variant carriers and LFS-associated cancers are documented.
  • No entry for c.63C>T, p.Asp21=, or p.D21= was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/TP53/fulltext/Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf.txt.
Sources
PP4 VCEPNot assessed: the VCEP requires multigene-panel detection at VAF 5-35%, but no qualifying VAF or panel result is available. Details ▾Hide ▴
Reasoning

The TP53 VCEP PP4 rule is a somatic low-VAF rule requiring the variant to have been detected on multigene panel testing, with Moderate requiring at least 2 independent observations at VAF 5-25% and Supporting requiring observation at VAF 5-35%. The available evidence reports cancer-cohort observations but provides no qualifying VAF measurements, no multigene-panel detection, and no evidence that the variant was identified in a blood specimen under this rule. PP4 is therefore not assessed.

VCEP rule
Moderate: At least 2 independent observations of the variant with VAF 5-25%. Supporting: Observation of the variant with VAF 5-35% (i.e., once or multiple times with VAF >25-35% and/or once with VAF 5-25%).
Evidence considered
  • The VCEP PP4 rule requires observation on multigene panel testing at VAF 5-35%; the available case literature gives counts of breast-cancer patients but no VAF or multigene-panel result.
  • PMID:32000721, experimental context: TP53 exon and flanking-region PCR followed by direct Sanger sequencing in cancer patients and controls; no variant-specific VAF was reported.
Still missing
  • No qualifying variant allele fraction or multigene-panel blood-testing result is available for PP4.
Sources
BS2 VCEPNot assessed: one healthy female control was reported, but age, unrelatedness, single-source status, and the required count of qualifying women are unavailable. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available evidence. gnomAD reports homozygotes but does not provide the VCEP-required count of unrelated females aged at least 60 years without cancer from one source. PMID:32000721 reports one healthy female control carrying c.63C>T, but does not establish that she was at least 60 years old, and one individual is below the minimum required for any BS2 strength. The available evidence therefore cannot evaluate the VCEP's age, sex, cancer-free, unrelatedness, and single-source requirements.

VCEP rule
≥ 8 unrelated females who have reached at least 60 years of age without cancer. These individuals all must have come from a single source (single lab, database, etc). Cases cannot be counted across sources. Individuals with a diagnosis of sarcoma ≥ 61 years of age should not be counted towards the BS2 total.
Evidence considered
  • gnomAD v4.1 reports 4 homozygotes overall, but the supplied gnomAD data do not identify sex, age, cancer status, unrelatedness, or a single source for BS2 counting.
  • Manoharan et al. (PMID:32000721), Table 3, reports c.63C>T in 2 breast-cancer patients and 1 female healthy control; the paper does not provide the healthy control's age or establish the VCEP BS2 requirements.
Still missing
  • A single-source cohort or database record identifying unrelated female carriers aged at least 60 years without cancer is required.
  • The number of qualifying women and any sarcoma diagnoses at or after age 61 are not available.
Sources
BS4 VCEPNot assessed: no affected family members with variant-negative testing or other family-level non-segregation evidence is documented. Details ▾Hide ▴
Reasoning

The TP53 VCEP defines BS4 as lack of segregation in affected family members diagnosed with LFS-associated cancers. No affected family members, family testing results, pedigree, or non-segregation observation is documented. Cohort observations of unrelated individuals and a healthy control do not establish lack of segregation within a family. Therefore BS4 cannot be assessed.

VCEP rule
Lack of segregation in affected family members (i.e. family members diagnosed with LFS-associated cancers as described in Table of LFS Cancers and Points for PS2 and PP1 Code Application).
Evidence considered
  • No family-level non-segregation result is present in the reviewed case evidence.
  • PMID:32000721 reports unrelated breast-cancer patients and a healthy control, not affected relatives tested for segregation.
  • PMID:20436704 reports a population cohort and matched non-malignant tissue/blood, not affected family members with non-segregation.
  • PMID:18798306 reports a population linkage-disequilibrium cohort and no family segregation result.
Still missing
  • No family pedigree or affected family members are documented.
  • No family-level variant testing demonstrates lack of segregation.
Sources
Not applicable · 16· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.63C>T is synonymous p.(Asp21=), with SpliceAI maximum delta 0.004 and no null or canonical splice consequence. Details ▾Hide ▴
Reasoning

NM_000546.5:c.63C>T is a synonymous SNV, NP_000537.3:p.(Asp21=), in exon 2, not a null variant, canonical splice-site variant, initiation-codon variant, or deletion. The case evidence reports synonymous_variant and SpliceAI max delta 0.004, with no predicted splice impact. The governing PVS1 flowchart and splicing worksheet were searched for c.63C>T, p.Asp21=, and p.D21=; neither file contains an entry for this variant. Therefore the VCEP PVS1 rule is not applicable, and no PVS1 strength is assigned.

VCEP rule
Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease.
Evidence considered
  • Variant normalization: NM_000546.5:c.63C>T; NP_000537.3:p.(Asp21=) / p.(D21=); exon 2; consequence class synonymous; canonical_splice_consensus false.
  • VEP consequence: synonymous_variant; variant class SNV.
  • SpliceAI scores: DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, DS_DL 0.001; maximum delta 0.004.
  • PVS1-Flowchart.pdf.txt searched for c.63C>T, p.Asp21=, and p.D21=; no matching entry was found.
  • PVS1-Splicing-Worksheet.xlsx.txt searched for c.63C>T, p.Asp21=, and p.D21=; no matching entry was found.
Still missing
  • No entry for c.63C>T, p.Asp21=, or p.D21= was found in PVS1-Flowchart.pdf.txt.
  • No entry for c.63C>T, p.Asp21=, or p.D21= was found in PVS1-Splicing-Worksheet.xlsx.txt.
Sources
PS1 N/ANot applicable: c.63C>T is synonymous p.Asp21=, so it creates no alternate amino-acid change eligible for the VCEP's PS1 comparison. Details ▾Hide ▴
Reasoning

The variant is synonymous, TP53 c.63C>T (p.Asp21=), so it does not produce an alternate amino-acid change for comparison under PS1. The VCEP permits PS1 only for variants asserted as pathogenic or likely pathogenic following TP53 VCEP specifications; the available exact-variant reports describe rs1800369/D21D as a synonymous polymorphism or uncertain/likely benign finding, not as a VCEP-established pathogenic or likely pathogenic comparator.

VCEP rule
Can be applied to variants asserted as Pathogenic following the TP53 VCEP’s specifications. ... Can be applied to variants asserted as Likely Pathogenic following the TP53 VCEP’s specifications.
Evidence considered
  • Case normalization identifies NM_000546.5:c.63C>T as NP_000537.3:p.(Asp21=), a synonymous variant.
  • Lee et al. 2010 (PMID:20436704) reports rs1800369C>T [D21D] as a germline variant likely representing a polymorphism, with MAF=0.392 in the Korean NSCLC cohort.
  • Manoharan et al. 2020 (PMID:32000721) reports c.63C>T/p.Asp21Asp in 2 breast-cancer patients and 1 healthy control and classifies it as a silent variant of uncertain significance.
  • The TP53 VCEP PS1 specification permits comparison only with variants asserted as pathogenic or likely pathogenic following the VCEP specifications.
Sources
PS3 N/ANot applicable: the TP53 VCEP PS3 functional pathway covers missense variants and small in-frame deletions, whereas c.63C>T is synonymous and has no worksheet entry. Details ▾Hide ▴
Reasoning

The variant is synonymous, NM_000546.5:c.63C>T (p.Asp21=; p.D21=), not a missense variant or small in-frame deletion. The TP53 VCEP functional flowchart and Functional-worksheet.xlsx govern protein-function PS3 application for missense variants and small deletions; the worksheet was searched under c.63C>T, p.Asp21=, and p.D21= with no matching entry. Therefore the named functional PS3 assay pathway does not apply to this variant. The case literature reviewed for the exact variant reports no variant-specific functional assay, and the isolated immunohistochemistry observation in PMID:32000721 does not identify this variant.

VCEP rule
Non-functional on Kato et al. data **AND** loss of function (LOF) by the majority of other eligible assays
Evidence considered
  • Flowchart-for-application-of-functional-rule-codes.pdf: the functional rows are limited to missense variants with Kato data, or missense variants with no Kato data and small deletions.
  • Functional-worksheet.xlsx, Supplementary Table S3: searches for c.63C>T, p.Asp21=, and p.D21= returned no matching row; the displayed table contains amino-acid substitution and deletion assay assignments, not this synonymous variant.
  • PMID:32000721: c.63C>T/p.Asp21Asp was reported, but the paper did not provide a variant-specific functional assay; one silent-variant p53-IHC result was not identified as c.63C>T.
Still missing
  • No matching c.63C>T, p.Asp21=, or p.D21= entry was found in Functional-worksheet.xlsx.
  • No synonymous-variant PS3 pathway is provided by Flowchart-for-application-of-functional-rule-codes.pdf.
  • The exact-variant literature reviewed did not provide a variant-specific functional assay; PMID:32000721 reported an unidentified silent-variant immunohistochemistry result that cannot be assigned to c.63C>T.
Sources
PM1 N/ANot applicable: p.Asp21= is synonymous at codon 21, outside the VCEP's missense PM1 codons 175, 245, 248, 249, 273, and 282. Details ▾Hide ▴
Reasoning

The TP53 VCEP PM1 rule is restricted to missense variants in codons 175, 245, 248, 249, 273, or 282, or germline missense variants meeting the named cancerhotspots.org occurrence routes. This variant is synonymous at codon 21 and is not eligible for either missense route; no domain-table entry is present for TP53.

VCEP rule
Missense variants within the following codons using transcript NM_00546.4: 175, 245, 248, 249, 273, 282. This code weight can also be used for germline missense variants seen in cancerhotspots.org with ≥ 10 somatic occurrences for the same amino acid change. ... Missense variants seen in cancerhotspots.org with 2-9 somatic occurrences for the same amino acid change.
Evidence considered
  • The VCEP PM1 rule lists only missense codons 175, 245, 248, 249, 273, and 282, plus named cancerhotspots.org missense occurrence routes.
  • The assessed variant is synonymous c.63C>T (p.Asp21=), codon 21, and therefore cannot satisfy either PM1 missense route.
  • vcep_materials.json domain_tables is empty for TP53; there is no authoritative domain-table entry requiring an additional residue-domain assessment.
Sources
PM3 VCEPNot applicable: the TP53 VCEP explicitly states that PM3 does not apply to TP53/Li-Fraumeni syndrome. Details ▾Hide ▴
Reasoning

The ClinGen TP53 VCEP specification explicitly excludes PM3 for TP53/Li-Fraumeni syndrome. Therefore, phase, affected-proband observations, and co-occurrence with pathogenic variants cannot activate PM3 under this governing framework.

VCEP rule
This rule does not apply to TP53/Li-Fraumeni syndrome.
Evidence considered
  • ClinGen TP53 VCEP specification v2.4, PM3 instructions: the rule is explicitly excluded for TP53/Li-Fraumeni syndrome.
Sources
PM4 VCEPNot applicable: the VCEP marks PM4 not applicable, and synonymous p.(Asp21=) causes no protein-length change. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly marks PM4 as not applicable. Independently, this variant is a synonymous SNV with no protein-length change, not an in-frame deletion, insertion, or stop-loss variant.

VCEP rule
Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.
Evidence considered
  • The TP53 VCEP CSPEC entry lists PM4 applicability as Not applicable.
  • Variant normalization identifies a synonymous SNV, NP_000537.3:p.(Asp21=), with no protein-length change.
Sources
cspec ↗pvs1_variant_assessment
PM5 N/ANot applicable: c.63C>T is synonymous p.Asp21=, whereas every VCEP PM5 route requires a missense variant at the same amino-acid residue. Details ▾Hide ▴
Reasoning

The TP53 VCEP PM5 specification requires a missense variant at an amino-acid residue with previously established pathogenic or likely pathogenic missense variants. c.63C>T is synonymous p.Asp21=, not missense, so PM5 does not apply regardless of same-residue comparator availability.

VCEP rule
Missense variant at an amino acid residue where ≥2 different missense variants previously determined to be pathogenic according to the TP53 VCEP’s specifications have been seen before. ... Missense variant at an amino acid residue where 1 different missense variant previously determined to be pathogenic according to the TP53 VCEP’s specifications has been seen before. ... Missense variant at an amino acid residue where 1 different missense variant previously determined to be likely pathogenic according to the TP53 VCEP’s specifications has been seen before. **The previously seen likely pathogenic variant must have clinical data that demonstrates pathogenicity (i.e. PS2, PS4, PP1) in order for it to count towards PM5_Supporting code application.**
Evidence considered
  • The variant consequence is synonymous, p.Asp21=, not missense.
  • The PM5 candidate collection records zero eligible same-residue missense candidates because the assessed consequence class is synonymous.
  • The VCEP PM5 rules specify strong, moderate, and supporting routes only for missense variants at a residue with previously established pathogenic or likely pathogenic missense variants.
Sources
cspec ↗pm5_candidates
PM6 VCEPNot applicable: the TP53 VCEP drops PM6 and requires all de novo evidence to be evaluated through PS2. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly makes PM6 not applicable and states that de novo evidence is handled exclusively through PS2. No PM6 code can therefore be assigned under this VCEP framework.

VCEP rule
To avoid redundancy and increase consistency, the TP53 VCEP has opted to drop PM6 and use PS2 exclusively for _de novo_ evidence.
Evidence considered
  • The VCEP criterion entry marks PM6 as Not applicable.
  • The VCEP instructions state that PM6 is dropped and PS2 is used exclusively for de novo evidence.
Sources
PP2 VCEPNot applicable: the TP53 VCEP explicitly designates PP2 as not applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly marks PP2 as not applicable.

VCEP rule
Not applicable
Evidence considered
  • The TP53 VCEP criteria entry for PP2 has applicability set to Not applicable.
Sources
PP5 VCEPNot applicable: the TP53 VCEP explicitly prohibits use of PP5. Details ▾Hide ▴
Reasoning

The TP53 VCEP designates PP5 as not applicable and instructs that it is not for use.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • TP53 VCEP criterion entry for PP5: not applicable for this VCEP.
Sources
BS3 N/ANot applicable: the TP53 VCEP BS3 functional pathway covers missense variants and small in-frame deletions, whereas c.63C>T is synonymous and has no worksheet entry. Details ▾Hide ▴
Reasoning

The variant is synonymous, NM_000546.5:c.63C>T (p.Asp21=; p.D21=), not a missense variant or small in-frame deletion. The TP53 VCEP functional flowchart and Functional-worksheet.xlsx govern protein-function BS3 application for missense variants and small deletions; the worksheet was searched under c.63C>T, p.Asp21=, and p.D21= with no matching entry. Therefore the named functional BS3 assay pathway does not apply to this variant. The exact-variant literature reviewed provides no variant-specific functional assay demonstrating preserved protein function.

VCEP rule
Functional on Kato et al. data **AND** no loss of function (LOF) by the majority of available eligible assays
Evidence considered
  • Flowchart-for-application-of-functional-rule-codes.pdf: the functional rows are limited to missense variants with Kato data, or missense variants with no Kato data and small deletions.
  • Functional-worksheet.xlsx, Supplementary Table S3: searches for c.63C>T, p.Asp21=, and p.D21= returned no matching row; no pre-assigned BS3 code exists for this synonymous variant.
  • PMID:32000721: c.63C>T/p.Asp21Asp was reported without a variant-specific functional assay; the paper's nonspecific silent-variant IHC observation cannot support BS3 for this variant.
Still missing
  • No matching c.63C>T, p.Asp21=, or p.D21= entry was found in Functional-worksheet.xlsx.
  • No synonymous-variant BS3 pathway is provided by Flowchart-for-application-of-functional-rule-codes.pdf.
  • The exact-variant literature reviewed did not provide a variant-specific functional assay demonstrating preserved protein function.
Sources
BP1 VCEPNot applicable: the TP53 VCEP excludes BP1 because truncating variants account for only a portion of disease-causing variants in these genes. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly states that BP1 does not apply to these genes because truncating variants account for only a portion of disease-causing variants.

VCEP rule
This rule code does not apply to these genes, as truncating variants account for only a portion of disease causing variants.
Evidence considered
  • The TP53 VCEP BP1 instructions state: This rule code does not apply to these genes, as truncating variants account for only a portion of disease causing variants.
Sources
BP2 VCEPNot applicable: the TP53 VCEP marks BP2 as not applicable, regardless of phase or co-occurrence with pathogenic variants. Details ▾Hide ▴
Reasoning

The ClinGen TP53 VCEP specification marks BP2 as not applicable. Consequently, observations of this synonymous TP53 variant in trans or cis with pathogenic or likely pathogenic variants, whether phase-confirmed or phase-unknown, cannot be used to apply BP2 under this framework.

VCEP rule
Not applicable
Evidence considered
  • ClinGen TP53 VCEP specification v2.4, BP2 applicability: Not applicable.
Sources
BP3 VCEPNot applicable: the VCEP marks BP3 not applicable, and synonymous p.(Asp21=) is not an in-frame deletion or insertion. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly marks BP3 as not applicable. Independently, this variant is synonymous p.(Asp21=), not an in-frame deletion or insertion in a repetitive region without known function.

VCEP rule
In frame-deletions/insertions in a repetitive region without a known function.
Evidence considered
  • The TP53 VCEP CSPEC entry lists BP3 applicability as Not applicable.
  • Variant normalization identifies a synonymous SNV, NP_000537.3:p.(Asp21=), rather than an in-frame deletion or insertion.
Sources
cspec ↗pvs1_variant_assessment
BP5 VCEPNot applicable: the TP53 VCEP explicitly marks BP5 as not applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP designates BP5 as not applicable and provides no usable BP5 rule for this VCEP.

VCEP rule
Not applicable
Evidence considered
  • TP53 VCEP criterion entry for BP5: applicability is Not applicable and instructions are Not applicable.
Sources
BP6 VCEPNot applicable: the TP53 VCEP explicitly prohibits use of BP6. Details ▾Hide ▴
Reasoning

The TP53 VCEP designates BP6 as not applicable and instructs that it is not for use.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • TP53 VCEP criterion entry for BP6: not applicable for this VCEP.
Sources

Identifiers

Gene
TP53
Transcript
NM_000546.5
Coding (HGVS c.)
NM_000546.5:c.63C>T
Protein (HGVS p.)
NP_000537.3:p.(Asp21=)
GRCh38
chr17:7676532 G>A
GRCh37
chr17:7579850 G>A
Location and type
Exon 2 · synonymous
ClinVar
184112

Gene diagram

Every interpreted variant in TP53, mapped onto the exon structure of NM_000546.5. Select a row to find it on the plot.

TP53NM_000546.5
Fetching transcript structure from UCSC…
gnomAD v4.1 387 / 1,614,004 alleles AF 0.00024 · 4 homozygotes · FAF 0.00371
gnomAD v2.1 134 / 250,398 alleles AF 0.000535 · 2 homozygotes · FAF 0.00379
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0.00024 · 387 / 1,614,004 alleles · 4 hom · FAF 0.0037
South Asian369 / 91,088 0.00414 hom
Remaining individuals14 / 62,504 0.00022
Middle Eastern1 / 6,062 0.00016
European (non-Finnish)3 / 1,180,010 2.5e-06
0 alternate alleles recorded in 6 other groups: Admixed American, European (Finnish), Amish, East Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 0.00054 · 134 / 250,398 alleles · 2 hom · FAF 0.0038
South Asian134 / 30,516 0.00442 hom
0 alternate alleles recorded in 7 other groups: African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Remaining individuals.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.000239776; MAF= 0.02398%, 387/1614004 alleles, homozygotes = 4) and has highest observed frequency in the South Asian population (AF= 0.00405103; MAF= 0.40510%, 369/91088 alleles, homozygotes = 4); grpmax FAF= 0.0037098.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.000535148; MAF= 0.05351%, 134/250398 alleles, homozygotes = 2) and has highest observed frequency in the South Asian population (AF= 0.00439114; MAF= 0.43911%, 134/30516 alleles, homozygotes = 2); grpmax FAF= 0.00378627.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0004893964110929853, 9/18390 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat +87 bp
0.004
SpliceAI acceptor gainat +1 bp
0.001
SpliceAI donor lossat -11 bp
0.001
SpliceAI donor gainat -338 bp
0.003
Pangolin splice lossmagnitude shown
-0.013
Pangolin splice gain
0.006

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

BP4 SupportingVCEPMet at supporting: maximum SpliceAI delta 0.004 is below the TP53 VCEP BP4 silent-variant threshold of 0.1. Details ▾Hide ▴
Reasoning

The variant is a synonymous exon 2 substitution, not a canonical ±1,2 splice-site variant. The TP53 VCEP BP4 supporting rule for silent variants outside ±1,2 positions requires SpliceAI ≤ 0.1. c.63 is not within the canonical splice-site positions, and the observed SpliceAI component scores are DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, and DS_DL 0.001, with maximum delta 0.004. Therefore BP4 Supporting is met. No exact c.63C>T/p.Asp21=/p.D21= row was found in the governing PP3-BP4 lookup spreadsheet; the separate single-amino-acid-deletions spreadsheet contains only the different p.Asp21del/c.61_63delGAC deletion at this position.

VCEP rule
**Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1
Evidence considered
  • NM_000546.5:c.63C>T is synonymous in exon 2 and is outside the canonical ±1,2 splice-site positions.
  • SpliceAI result: DS_AG=0.001, DS_AL=0.004, DS_DG=0.003, DS_DL=0.001; maximum delta=0.004.
  • The TP53 VCEP flowchart assigns BP4 to silent variants with SpliceAI <= 0.1, and the VCEP rule specifies this path for silent variants outside ±1,2 positions.
  • PP3-BP4-codes.xlsx was searched for c.63C>T, p.Asp21=, and p.D21=; no exact matching row was found.
  • TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx was searched; its p.Asp21del/c.61_63delGAC row is not the assessed synonymous variant.
Still missing
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in PP3-BP4-codes.xlsx.
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx; the located p.Asp21del/c.61_63delGAC row is a different variant.
Sources
BP7 SupportingVCEPMet at supporting: synonymous c.63C>T is outside the core splice motif and has maximum SpliceAI delta 0.004, below the 0.1 threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous and lies outside the TP53 VCEP core splice motif, defined as the last three nucleotides and first nucleotide of the exon. The governing BP7 supporting rule requires a synonymous variant outside that motif and SpliceAI ≤ 0.1, with BP4 met. c.63 is outside the exon-boundary core motif, BP4 Supporting is met, and the maximum SpliceAI delta is 0.004 (DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, DS_DL 0.001). BP7 Supporting is therefore met without using nucleotide conservation. No exact variant row was found in PP3-BP4-codes.xlsx or in the single-amino-acid-deletions spreadsheet; the latter contains a distinct p.Asp21del entry.

VCEP rule
A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023 (PMID: 37352859).
Evidence considered
  • NM_000546.5:c.63C>T is a synonymous exon 2 variant; the assessed coding position is outside the VCEP core splice motif of the last three nucleotides and first nucleotide of the exon.
  • SpliceAI result: DS_AG=0.001, DS_AL=0.004, DS_DG=0.003, DS_DL=0.001; maximum delta=0.004.
  • The TP53 VCEP flowchart states that BP7 is added to BP4 for a silent variant outside the core splice motif when SpliceAI <= 0.1.
  • The reviewed exact-variant paper extracts did not identify a variant-specific RNA splicing assay for c.63C>T; no RNA assay is needed for the VCEP BP7 Supporting path.
  • PP3-BP4-codes.xlsx and TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx were searched for c.63C>T, p.Asp21=, and p.D21=; neither contained an exact row.
Still missing
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in PP3-BP4-codes.xlsx.
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx; the located p.Asp21del/c.61_63delGAC row is a different variant.
  • No variant-specific RNA splicing assay result was identified in the reviewed case evidence; BP7 Supporting is evaluated from the VCEP SpliceAI path, not the stronger RNA-assay path.
Sources
PP3 VCEPNot met: maximum SpliceAI delta 0.004 is below the TP53 VCEP PP3 threshold of 0.2 for exonic silent splice variants. Details ▾Hide ▴
Reasoning

The variant is synonymous in exon 2 (NM_000546.5:c.63C>T; NP_000537.3:p.(Asp21=), p.(D21=)). The TP53 VCEP PP3 supporting rule covers exonic silent variants when SpliceAI is ≥ 0.2. The available SpliceAI result has DS_AG 0.001, DS_AL 0.004, DS_DG 0.003, and DS_DL 0.001, with a maximum delta of 0.004, so the PP3 splice-impact threshold is not met. The governing PP3-BP4 lookup spreadsheet was searched for c.63C>T, p.Asp21=, and p.D21= without an exact entry; the single-amino-acid-deletions spreadsheet was also searched and contains p.Asp21del/c.61_63delGAC, which is a different in-frame deletion rather than this synonymous variant.

VCEP rule
**Exonic (including silent variants and apparent “missense” variants or “single amino acid inframe deletions” for which there is a predicted splice effect) or Intronic Splice Variants (excluding ± 1,2 positions):** SpliceAI ≥ 0.2
Evidence considered
  • NM_000546.5:c.63C>T is a synonymous exon 2 variant, annotated NP_000537.3:p.(Asp21=) and NP_000537.3:p.(D21=).
  • SpliceAI result: DS_AG=0.001, DS_AL=0.004, DS_DG=0.003, DS_DL=0.001; maximum delta=0.004.
  • ClinGen TP53 VCEP Flowchart for application of PP3, BP4, and BP7: exonic splice variants, including silent variants with predicted splice effect, require SpliceAI >= 0.2 for PP3.
  • PP3-BP4-codes.xlsx was searched for c.63C>T, p.Asp21=, and p.D21=; no exact matching row was found.
  • TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx was searched; its p.Asp21del/c.61_63delGAC row is an in-frame deletion and not the assessed synonymous variant.
Still missing
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in PP3-BP4-codes.xlsx.
  • No exact c.63C>T, p.Asp21=, or p.D21= entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx; the located p.Asp21del/c.61_63delGAC row is a different variant.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).

9 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Recorded publications

  • High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H et al. · 2009
    No paper-specific finding is recorded.
    PMID 19336573 ↗
  • TP53 mutations in Korean patients with non-small cell lung cancer.
    Lee EB et al. · 2010
    The paper reports rs1800369C>T [D21D], corresponding to TP53 c.63C>T and p.(D21=), as a germ-line variant likely representing a polymorphism because it was present in matched non-malignant lung tissue and blood lymphocytes; it reported MAF 0.392.
    Names this variant
    PMID 20436704 ↗
    Quoted passage
    In addition to the somatic mutations, we observed 8 germ-line variants that likely represent polymorphisms because they were found in matched non-malignant lung tissues and blood lymphocytes (rs1800369C>T [D21D], minor allele frequency [MAF]=0.392;

    Results, paragraph 1

  • TP53 mutations in human cancer: database reassessment and prospects for the next decade.
    Leroy B et al. · 2014
    No paper-specific finding is recorded.
    PMID 24665023 ↗
  • Frequent occurrence of gastric cancer in Asian kindreds with Li-Fraumeni syndrome.
    Ariffin H et al. · 2015
    No paper-specific finding is recorded.
    PMID 25318593 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    No paper-specific finding is recorded.
    PMID 26467025 ↗
  • Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.
    No paper-specific finding is recorded.
    PMID 30816478 ↗
  • Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    Manoharan V et al. · 2020
    The paper explicitly reports TP53 c.63C>T, annotated as p.Asp21Asp, a synonymous variant in exon 2. It was observed in 2 breast cancer patients and 1 healthy female control and classified in Table 3 as a silent variant of uncertain significance; no variant-specific functional assay was reported.
    Names this variant
    PMID 32000721 ↗
    Quoted passage
    There were also 2 silent variants with uncertain significance, of which, c.63C > T appeared in 2 BC patients and in 1 female healthy control

    Results, Analysis of TP53 sequence variants; Table 3, entry 14

  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.000239776; MAF= 0.02398%, 387/1614004 alleles, homozygotes = 4) and has highest observed frequency in the South Asian population (AF= 0.00405103; MAF= 0.40510%, 369/91088 alleles, homozygotes = 4); grpmax FAF= 0.0037098.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.000535148; MAF= 0.05351%, 134/250398 alleles, homozygotes = 2) and has highest observed frequency in the South Asian population (AF= 0.00439114; MAF= 0.43911%, 134/30516 alleles, homozygotes = 2); grpmax FAF= 0.00378627.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0004893964110929853, 9/18390 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Benign (6 clinical laboratories) and as Likely benign (5 clinical laboratories). (ClinVarID = 184112)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).

Functional

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.